Jallet et al. 1999. Chimeric lyssavirus glycoproteins with increased immunological potential. Journal of virology. vol. 73. No. 1, pp. 225-233.* |
Mebatsion et al. 1995. Mokola virus glycoprotein and chimeric proteins can replace rabies virus glycoprotein in the rescue of infectious defective rabies virus particles. Journal of Virology. vol. 69. No. 3, pp. 1444-1451.* |
Tine et al. 1996. NYVAC-P∫7: a poxvirus-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. Infection and Immunity. vol. 64, No. 9, pp. 3833-3844.* |
Liu et al. 1994. Polynucleotide vaccines: a potential new generation of vaccines. Proc. Eur. Assoc. Vet. Pharmacol. Toxicol. 6 Meet., 301. Abstract only.* |
Ertl. et al. 1996. Novel vaccine approaches. Journal of Immunology. vol. 156, pp. 3579-3582.* |
Paoletti et al. PNAS. 1996; 93(21): 11349-53.* |
Macy et al. Vet Clin North Am Small Anim Pract. 1996; 26(1): 103-109, abstract only.* |
Amengual, B. et al., 1997, “Evolution of European bat lyssaviruses”, J. Gen. Virol. 78:2319-2328. |
Bahloul, C. et al, 1998, “DNA-based immunization for exploring the enlargement of immunological cross-reactivity against the lyssaviruses”, Vaccine 16:417-425. |
Benmansour et al., 1991, “Antigenicity of rabies virus glycoprotein”, J. Virol. 65(8):4198-4203. |
Buffet et al., 1999, “P. falciparum domain mediating adhesion to chondroitin sulfate A: A receptor for human placental infection”, PNAS, 96(22):12743-48. |
Coulon et al., 1998, “An avirulent mutant of rabies virus is unable to infect motoneurons in vivo and in vitro”, J. Virol. 72(1):273-278. |
Dietzschold et al., 1990, “Structural and immunological characterization of a linear virus-neutralizing epitope of the rabies virus glycoprotein and its possible use in a synthetic vaccine”, J Virol. 64(8):3804-3809. |
Donnelly, J. et al., 1997, “DNA Vaccines”, Annu. Rev. Immunol. 15:617-648. |
European Commission COST/STD-3, 1996, “Advantages of combined vaccines”, Vaccine, 14(7):693-700. |
Gaudin, Y., et al., 1991, “Reversible conformational changes and fusion activity of rabies virus glycoprotein”, J. Virol. 65(9):4853-4859. |
Gaudin, Y. et al., 1995, “Biological function of the low-pH, fusion-inactive conformation of rabies virus glycoprotein (G): G is transported in a fusion-inactive state-like conformation”, J. Virol. 69(9):5528-5533. |
Gaudin, Y., 1997, “Folding of rabies virus glycoprotein: epitope acquisition and interaction with endoplasmic reticulum chaperones”, J. Virol. 71(15):3742-3750. |
Lafay et al., 1996, “Immunodominant epitopes defined by a yeast-expressed library of random fragments of the rabies virus glycoprotein map outside major antigenic sites”, J. Gen. Virol. 77:339-346. |
Lafon et al., 1983, “Antigenic sites on the CVS rabies virus glycoprotein: analysis with monoclonal antibodies”, J. Gen. Virol. 64:843-845. |
M. Lafon et al., 1985, “Use of a monoclonal antibody for quantitation of rabies vaccine glycoprotein by enzyme immunoassay”, J. Biol. Standard 13:295-301. |
Lang, J. et al., 1997, “Randomised Feasibility trial of pre-exposure rabies vaccination with DTP-IPV in infants”, The Lancet 349:1663-1665. |
Lodmell, D. et al., 1998a, “DNA immunization protects nonhuman primates against rabies virus”, Nature Med. 4(8):949-952. |
Lodmell, D. et al., 1998b, “Gene gun particle-mediated vaccination with plasmid DNA confers protective immunity against rabies virus infection”, Vaccine 16(2/3):115-118. |
MacFarlan, R. et al., 1984, “T cell responses to cleaved rabies virus glycoprotein and to synthetic peptides”, J. Immunol. 133(5):2748-2752. |
Pastoret, P-P. et al., 1997, “Vaccination against rabies”, In Veterinary Vaccinology, Pastoret, P-P. et al., Eds. (Elsevier): 616-628. |
Perrin, P., et al., 1985, “Rabies immunosome (subunit vaccine) structure and immunogenicity”, Vaccine, 3:325-332. |
Perrin, P. et al., 1986, “The influence of the type of immunosorbent on rabies antibody EIA; advantages of purified glycoprotein over whole virus”, J. Biol. Standard. 14:95-102. |
Perrin, P., 1996a, “Techniques for the preparation of rabies conjugates”, In Laboratory techniques in rabies, Fourth edition (Eds Meslin, F-X; Kaplan, M. and Koprowski, H.) WHO, Geneva:433-445. |
Perrin, P. et al., 1996b, “The antigen-specific cell-mediated immune response in mice is suppressed by infection with pathogenic lyssaviruses”, Res. Virol. 147:289-299. |
Smith, J. et al., 1996, “A rapid fluorescent focus inhibition test (RFFIT) for determining virus-neutralizing antibody”, In Laboratory techniques in rabies, Fourth edition (Eds Meslin, F-X; Kaplan, M. and Koprowski, H.) WHO, Geneva:181-189. |
Thomson, S. et al., 1998, “Delivery of multiple CD8 cytotoxic cell epitopes by DNA vaccination”, J. Immunol. 160(4):1717-1723. |
Tuffereau et al., 1998, “Neuronal cell surface molecules mediate specific binding to rabies virus glycoprotein expressed by a recombinant baculovirus on the surfaces of lepidopteran cells”, J. Virol. 72(2):1085-1091. |
Wunner, W. et al. 1985, “Localization of immunogenic domains on the rabies virus glycoprotein”, Ann. Inst. Pasteur, 136 E:353-362. |
Xiang, Z. et al., 1994, “Vaccination with a plasmid vector carrying the rabies virus glycoprotein gene induces protective immunity against rabies virus”, Virol. 199:132-140. |